CraigEColeMD

Clotting Disorder, Hematologic Oncology

Gundersen Lutheran center for cancer and blood disorders

Dr. Cole is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
401 W Greenlawn Ave
Lansing, MI 48910
Phone+1 517-975-9500

Fax+1 517-975-9520

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

PubMed

BPI24-017: Optimizing the Implementation of New Therapies in Multiple Myeloma.
Kirollos Hanna, Craig Emmitt Cole, David Vesole, Mary Stanley, Kimberly Demirhan
Journal of the National Comprehensive Cancer Network. 2024-04-05
3 citations
Creating Equitable and Inclusive Clinical Trials for Multiple Myeloma.
Monique Hartley-Brown, Craig E Cole, Pamela Price, Michael Andreini, George Mulligan
Clinical Lymphoma, Myeloma & Leukemia. 2024-01-01
11 citations
Addressing the disparities: the approach to the African American patient with multiple myeloma.
Manisha Bhutani, Brandon J Blue, Craig Cole, Ashraf Z Badros, Saad Z Usmani
Blood Cancer Journal. 2023-12-18

Abstracts/Posters

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Aneuploidy Is Associated with Inferior Survival in Relapsed Refractory Multiple Myeloma Patients
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Craig E. Cole, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all